These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 32089218

  • 1. Luspatercept in Myelodysplastic Syndromes: Who and When?
    Komrokji RS.
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
    [Abstract] [Full Text] [Related]

  • 2. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
    Chan O, Komrokji RS.
    Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
    [Abstract] [Full Text] [Related]

  • 3. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C, Syed YY.
    Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
    [Abstract] [Full Text] [Related]

  • 4. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.
    Verma A, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R.
    J Clin Invest; 2020 Feb 03; 130(2):582-589. PubMed ID: 31961337
    [Abstract] [Full Text] [Related]

  • 5. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
    Della Porta MG, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U.
    Lancet Haematol; 2024 Sep 03; 11(9):e646-e658. PubMed ID: 39038479
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development of luspatercept to treat ineffective erythropoiesis.
    Kubasch AS, Fenaux P, Platzbecker U.
    Blood Adv; 2021 Mar 09; 5(5):1565-1575. PubMed ID: 33687432
    [Abstract] [Full Text] [Related]

  • 10. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
    Molica M, Rossi M.
    Expert Opin Biol Ther; 2024 Apr 09; 24(4):233-241. PubMed ID: 38555469
    [Abstract] [Full Text] [Related]

  • 11. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
    Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A.
    Lancet Oncol; 2017 Oct 09; 18(10):1338-1347. PubMed ID: 28870615
    [Abstract] [Full Text] [Related]

  • 12. Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS.
    Komrokji RS.
    Curr Hematol Malig Rep; 2019 Aug 09; 14(4):346-351. PubMed ID: 31203517
    [Abstract] [Full Text] [Related]

  • 13. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
    Mies A, Hermine O, Platzbecker U.
    Curr Hematol Malig Rep; 2016 Dec 09; 11(6):416-424. PubMed ID: 27595736
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
    Schulz F, Nachtkamp K, Kasprzak A, Gattermann N, Haas R, Germing U.
    Expert Rev Hematol; 2021 Jun 09; 14(6):509-516. PubMed ID: 34161752
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Activin receptor ligand traps in chronic kidney disease.
    Jelkmann W.
    Curr Opin Nephrol Hypertens; 2018 Sep 09; 27(5):351-357. PubMed ID: 29847322
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
    Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G.
    Lancet; 2023 Jul 29; 402(10399):373-385. PubMed ID: 37311468
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.